WuXi AppTec Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 33,834

Employees

  • Stock Symbol
  • 603259

Stock Symbol

  • Investments
  • 85

  • Share Price
  • $21.12
  • (As of Friday Closing)

WuXi AppTec General Information

Description

Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.

Contact Information

Formerly Known As
WuXi AppTec New Drug Development
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • Number 288, Fute Middle Road, Waigaoqiao Free Trade Zone
  • Pudong New Area
  • Shanghai, 200131
  • China
+86 021
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Stock Exchange
SHG
Vertical(s)
Corporate Office
  • Number 288, Fute Middle Road, Waigaoqiao Free Trade Zone
  • Pudong New Area
  • Shanghai, 200131
  • China
+86 021

WuXi AppTec Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

WuXi AppTec Stock Performance

As of 20-Nov-2026, WuXi AppTec’s stock price is $21.12. Its current market cap is $65.2B with 3.03B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$21.12 $21.65 $12.33 - $25.79 $65.2B 3.03B 39.7M $1.32

WuXi AppTec Financials Summary

As of 30-Sep-2026, WuXi AppTec has a trailing 12-month revenue of $8.43B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 71,539,309 35,007,528 20,772,985 29,515,570
Revenue 8,434,571 6,320,977 5,468,838 5,701,978
EBITDA 4,659,814 3,719,554 1,946,049 1,959,704
Net Income 3,840,790 2,663,014 1,317,032 1,357,867
Total Assets 18,669,621 14,738,515 11,003,387 10,392,652
Total Debt 1,271,713 1,203,441 686,135 810,832
Public Fundamental Data provided by Morningstar, Inc. disclaimer

WuXi AppTec Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore WuXi AppTec‘s full profile, request access.

Request a free trial

WuXi AppTec Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, an
Biotechnology
Shanghai, China
33,834 As of 2025

Shenzhen, China
 

Beijing, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

WuXi AppTec Competitors (61)

One of WuXi AppTec’s 61 competitors is BGI Genomics, a Formerly VC-backed company based in Shenzhen, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BGI Genomics Formerly VC-backed Shenzhen, China
Pharmaron Formerly VC-backed Beijing, China
Twist Bioscience Formerly VC-backed South San Francisco, CA
HTG Molecular Diagnostics Formerly VC-backed Tucson, AZ
Molecular Cloning Laboratories Corporation South San Francisco, CA
You’re viewing 5 of 61 competitors. Get the full list »

WuXi AppTec Patents

WuXi AppTec Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11890281-B2 Shp2 phosphatase inhibitors and methods of making and using the same Active 24-Sep-2019
US-20210085677-A1 Shp2 phosphatase inhibitors and methods of making and using the same Active 24-Sep-2019
US-20240122925-A1 Shp2 phosphatase inhibitors and methods of making and using the same Inactive 24-Sep-2019
US-20220048888-A1 Pyrimidinyl-heteroaryloxy-naphthyl compounds and methods of use Pending 12-Sep-2018
US-10968203-B2 Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders Active 17-Mar-2017 C07D413/14
To view WuXi AppTec’s complete patent history, request access »

WuXi AppTec Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

WuXi AppTec Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore WuXi AppTec‘s full profile, request access.

Request a free trial

WuXi AppTec Investments & Acquisitions (85)

WuXi AppTec’s most recent deal was a Merger/Acquisition with BioDlink for . The deal was made on 27-Mar-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
BioDlink 27-Mar-2026 Merger/Acquisition Drug Discovery
D3 Bio 09-Dec-2025 Later Stage VC Biotechnology
Shengji Pharmaceutical 24-Jun-2025 Secondary Transaction - Private Biotechnology
Shengji Pharmaceutical 21-May-2025 Merger/Acquisition Biotechnology
D3 Bio 08-Apr-2024 Early Stage VC Biotechnology
You’re viewing 5 of 85 investments and acquisitions. Get the full list »

WuXi AppTec ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

12.83 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Laboratory Equipment and Services

Subindustry

of 67

Rank

Percentile

To view WuXi AppTec’s complete esg history, request access »

WuXi AppTec Exits (46)

WuXi AppTec’s most recent exit was on 24-Jun-2025 from Shengji Pharmaceutical. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Shengji Pharmaceutical 24-Jun-2025 Completed
Shengji Pharmaceutical 21-May-2025 Completed
Wisdo Health 05-Jan-2023 Completed
  • 12 buyers
Structure Therapeutics 01-Aug-2022 Completed
  • 23 buyers
Yilite Technology 11-Jun-2021 Secondary Transaction - Private Completed
You’re viewing 5 of 46 exits. Get the full list »

WuXi AppTec Affiliates

Subsidiaries (4)

Name Industry Location Year Founded
Crelux Grafelfing, Germany 2005
HD Biosciences Shanghai, China 2002
WuXi AppTec Investment Wuxi, China
WuXi AppTec (Cell and Gene Therapy Manufacturing Division) PA

WuXi AppTec FAQs

  • When was WuXi AppTec founded?

    WuXi AppTec was founded in 2000.

  • Where is WuXi AppTec headquartered?

    WuXi AppTec is headquartered in Shanghai, China.

  • What is the size of WuXi AppTec?

    WuXi AppTec has 33,834 total employees.

  • What industry is WuXi AppTec in?

    WuXi AppTec’s primary industry is Biotechnology.

  • Is WuXi AppTec a private or public company?

    WuXi AppTec is a Public company.

  • What is WuXi AppTec’s stock symbol?

    The ticker symbol for WuXi AppTec is 603259.

  • What is the current stock price of WuXi AppTec?

    As of 20-Nov-2026 the stock price of WuXi AppTec is $21.12.

  • What is the current market cap of WuXi AppTec?

    The current market capitalization of WuXi AppTec is $65.2B.

  • What is WuXi AppTec’s current revenue?

    The trailing twelve month revenue for WuXi AppTec is $8.43B.

  • Who are WuXi AppTec’s competitors?

    BGI Genomics, Pharmaron, Twist Bioscience, HTG Molecular Diagnostics, and Molecular Cloning Laboratories are some of the 61 competitors of WuXi AppTec.

  • What is WuXi AppTec’s annual earnings per share (EPS)?

    WuXi AppTec’s EPS for 12 months was $1.32.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process